Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

Major Depressive Disorder Clinical Trial

Official title:

A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00531947
• Other study ID #: S9303-P0605
• Status: Completed
• Phase: Phase 4
• First received: September 18, 2007
• Last updated: December 12, 2013
• Start date: July 2007
• Est. completion date: October 2010

Study information

• Verified date: December 2013
• Source: Somerset Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of adolescents (aged 12 through 17 years) with Major Depressive Disorder (MDD).

Description:

• Assess the safety and efficacy of EMSAM (selegiline transdermal system) versus placebo in adolescents (aged 12 through 17 years) who meet criteria for Major Depressive Disorder (MDD) without psychotic features, single or recurrent

Recruitment information / eligibility

• Status: Completed
• Enrollment: 308
• Est. completion date: October 2010
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

• Male / Female outpatients 12 to 17 years of age diagnosed with Major Depressive Disorder (MDD). (Must have a Children's Depression Rating Scale-Revised [CDRS-R] with a total score of at least 45 at screening.)

• Female patients must test negative on a pregnancy at visit 1.

• Weight and height must be greater than the 10th percentile according to age and height,

• Assent and consent must be given.

Exclusion Criteria:

• Have a serious or unstable medical illness, psychological condition, clinically significant laboratory or ECG result, hypersensitivity to selegiline, or any other condition that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study.

• Have a current or previous diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive disorder, pervasive development disorder or borderline personality disorder, as determined by the investigator.

• Have a risk of suicide

• Female patients who are either pregnant, nursing or have recently given birth.

• Use of any protocol prohibited medications or substances.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Selegiline Transdermal System
EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
• Placebo
Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study

Locations

Country	Name	City	State
United States	Dr. David Brown	Austin	Texas
United States	Dr. Alain Katic	Bellaire	Texas
United States	Dr. Arifulla Khan	Bellevue	Washington
United States	Dr. Mary Shemo	Charlottesville	Virginia
United States	Dr. Melissa DelBello	Cincinnati	Ohio
United States	Dr. Graham Emslie	Dallas	Texas
United States	Dr. Nelson Handal	Dothan	Alabama
United States	Dr. Elias Sarkis	Gainesville	Florida
United States	Dr. Ann Childress	Las Vegas	Nevada
United States	Dr. Mohammed Bari	National City	California
United States	Dr. Scott Segal	North Miami	Florida
United States	Dr. Leland Dennis	Oklahoma City	Oklahoma
United States	Dr. Christopher Kratochvil	Omaha	Nebraska
United States	Dr. Rory Murphy	Overland Park	Kansas
United States	Dr. Andrew Sediloo	Owensboro	Kentucky
United States	Dr. John Gilliam	Richmond	Virginia
United States	Dr. Michael McManus	SanDiego	California
United States	Dr. Bruce Waslick	Springfield	Massachusetts
United States	Dr. Mary Stedman	Tampa	Florida
United States	Dr. Irving Kolin	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Somerset Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12	A summary of the primary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score, as reported by the Child, at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.; CDRS-R total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.	baseline and 12 Weeks	No
Secondary	CGI-S - Week 12 (mITT w/LOCF Population)	A summary of the Clinical Global Impression of Severity (CGI-S) at baseline and Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. The CGI-s is the clinician's assessment of severity of illness (depression). Scores range from 1(minimum) to 7(maximum). A lower score indicates lower illness severity, a higher score indicates higher levels of illness severity.	Baseline and 12 Weeks	No
Secondary	CGI-C - Week 12 (mITT w/LOCF Population)	A summary of the Clinicians Global Impression of Change (CGI-C) Score at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. The CGI-c assesses the overall change in the severity of illness (depression). The clinician rates the subject's change based on a bipolar scale from 1(minimum; "Very much improved") to 7(maximum; "Very much worse"). A lower score indicates lower levels of depression as compared to baseline, a higher score indicates higher levels of depression as compared to baseline. A score of 4 ("Unchanged") indicates no change in illness compared to baseline. The scale is not calculated as a statistical change score; the clinician rates their impression of change overall.	12 Weeks	No
Secondary	CGI-C Percent Responders (mITT w/LOCF Population)	A summary of the CGI-C percent responders at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. CGI-C responders were defined as a score of 1 or 2 at the end of the study. A non-responder was defined as a score of =3 at end of study. Maximum score is 100%.	12 Weeks	No
Secondary	CDRS-R Total Score (Parent/Other) Week 12 (mITT w/LOCF Population)	A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.; CDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation.	Baseline and 12 Weeks	No
Secondary	CDRS-R Total Score (Best Description) Week 12 (mITT w/LOCF Population)	A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.; Best Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column.; CDRS-R (Best Description)total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.	12 Weeks	No
Secondary	CDRS-R Total Score (Child) Week 12 (mITT w/OC Population)	A summary of the secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Child), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC).; CDRS-R (Child) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.	12 Weeks	No
Secondary	CDRS-R Total Score (Parent/Other) Week 12 (mITT w/OC Population)	A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC).; CDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation.	12 Weeks	No
Secondary	CDRS-R Total Score (Best Description) Week 12 (mITT w/OC Population)	A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with observed cases (w/OC).; Best Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom area. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column.; CDRS-R (Best Description) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.	12 Weeks	No
Secondary	Physical Examination (Screening vs. EOS)	Number of physical examination findings that were normal at screening, but abnormal at end of study are presented. Four subjects receiving placebo and four subjects receiving EMSAM had abnormal findings on physical examination at the end of study that were normal at screening.	12 Weeks	Yes
Secondary	Urinalysis (Change From Baseline)	A summary of a secondary safety outcome measure, Urinalysis (Change from Baseline), by treatment assigned, is shown for the safety population. Mean changes from baseline are provided for PH and specific gravity.	12 Weeks	Yes
Secondary	Vital Signs-Heart Rate (Change From Baseline)	Summary mean change in heart rate measured in beats per minute (beats/min or BPM) (supine, standing, and orthostatic change)results for all subjects are presented.	12 Weeks	Yes
Secondary	Vital Signs-Blood Pressure (Change From Baseline)	Summary mean change in blood pressure (systolic/diastolic) measured in millimeters of mercury (mmHg) (supine, standing, and orthostatic change)results for all subjects are presented.	12 Weeks	Yes
Secondary	12 Lead ECG (Change From Baseline)	A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline) measured in milliseconds (msec), by treatment assigned, is shown for the safety population. Mean change from Baseline in PR interval, QRS duration, QT interval, and QTc (Bazett and Fridericia corrections) interval are presented.	12 Weeks	Yes
Secondary	12 Lead ECG (Change From Baseline)Ventricular Heart Rate	A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline)Ventricular Heart Rate measured in beats per minute(beats/min or BPM), by treatment assigned, is shown for the safety population. Mean change from baseline is presented.	12 Weeks	Yes
Secondary	Hematology - White Blood Cell (WBC) (Change From Baseline)	A summary of a secondary safety outcome measure, Hematology (Change from Baseline), by treatment assigned, is shown for the safety population. Mean change from Baseline in ABS BASOPHILS (X10^9/L), ABS EOSINOPHILS (X10^9/L), ABS LYMPHOCYTES (X10^9/L), ABS MONOCYTES (X10^9/L), and ABS NEUTROPHILS (X10^9/L) are presented.	12 Weeks	Yes
Secondary	Hematology - Hematocrit (Change From Baseline)	A summary of a secondary safety outcome measure, Hematology - Hematocrit(HCT)(Change from Baseline), by treatment assigned, is shown for the safety population.	12 Weeks	Yes
Secondary	Hematology - Hemoglobin (Change From Baseline)	A summary of a secondary safety outcome measure, Hematology - Hemoglobin(HGB)(Change from Baseline), by treatment assigned, is shown for the safety population.	12 Weeks	Yes
Secondary	Hematology - Red Blood Cell (Change From Baseline)	A summary of a secondary safety outcome measure, Hematology - Red Blood Cell (RBC)(Change from Baseline), by treatment assigned, is shown for the safety population.	12 Weeks	Yes